Compare XPL & TCRX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | XPL | TCRX |
|---|---|---|
| Founded | 1984 | 2018 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Precious Metals | Biotechnology: Pharmaceutical Preparations |
| Sector | Basic Materials | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 64.6M | 64.1M |
| IPO Year | N/A | 2021 |
| Metric | XPL | TCRX |
|---|---|---|
| Price | $0.74 | $1.15 |
| Analyst Decision | Strong Buy | Strong Buy |
| Analyst Count | 2 | 7 |
| Target Price | $1.20 | ★ $8.50 |
| AVG Volume (30 Days) | 228.6K | ★ 597.2K |
| Earning Date | 10-31-2025 | 03-04-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | N/A |
| EPS | ★ N/A | N/A |
| Revenue | N/A | ★ $8,423,000.00 |
| Revenue This Year | N/A | $286.83 |
| Revenue Next Year | N/A | N/A |
| P/E Ratio | N/A | N/A |
| Revenue Growth | ★ N/A | N/A |
| 52 Week Low | $0.54 | $0.88 |
| 52 Week High | $0.90 | $2.85 |
| Indicator | XPL | TCRX |
|---|---|---|
| Relative Strength Index (RSI) | N/A | 53.33 |
| Support Level | N/A | $1.13 |
| Resistance Level | N/A | $1.27 |
| Average True Range (ATR) | 0.00 | 0.08 |
| MACD | 0.00 | 0.02 |
| Stochastic Oscillator | 0.00 | 55.74 |
Solitario Resources Corp is exploration company engaging in acquiring, exploring, and developing zinc properties and other precious metals in safe jurisdictions in North and South America. It has joint venture interests in large, high-grade zinc development projects. The Florida Canyon Zinc Project in Peru is a development asset held jointly with Nexa Resources S.A., Golden Crest Project in South Dakota and the Lik Zinc Project represents a large-tonnage, high-grade development project in Alaska in partnership with Teck Resources. In addition, the company has an additional portfolio of exploration properties and royalties in the Americas.
TScan Therapeutics Inc is a biopharmaceutical company focused on the development of T-cell receptor (TCR) engineered T cell therapies (TCR-T) for the treatment of patients with cancer. The company's liquid tumor TCR-T therapy candidates, TSC-100 and TSC-101, are in development for the treatment of patients with hematologic malignancies to eliminate residual leukemia and prevent relapse after hematopoietic stem cell transplantation. It is also developing multiplexed TCR-T therapy candidates for the treatment of various solid tumors.